

16.1.5 Signatures of Sponsor's Responsible Medical Officer, Depending on the Regulatory Authority's Requirement, and Signature of Responsible Biostatistician

STUDY TITLE: A Phase 2a, Randomized, Observer-Blind, Placebo-Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

STUDY NUMBER: mRNA-1273-P201

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Sponsor's Responsible Medical Officer:

SIGNATURE: See esignature and date signed on last page of document.

Roderick McPhee, MD, PhD
Director, Clinical Development Infectious Diseases

Date

ModernaTX, Inc.
200 Technology Square
Cambridge, MA 02139
United States
Telephone: (b) (6) [REDACTED]
Email: roderick.mcphee@modernatx.com

Responsible Biostatistician:

SIGNATURE: See esignature and date signed on last page of document.

Wenmei Huang, PhD
Sr. Director, Biostatistics, Study Biostatistician Lead

Date

Signature Page for VV-CLIN-002045 v1.0

Approval	Wenmei Huang Clinical 24-Feb-2021 00:25:29 GMT+0000
----------	---

Approval	Roderick McPhee Medical 24-Feb-2021 00:26:53 GMT+0000
----------	---

Signature Page for VV-CLIN-002045 v1.0